Patents by Inventor Meena L. Narasimhan

Meena L. Narasimhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7803854
    Abstract: The Proteins of the PR-5 family having a lectin-like ? barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like ? barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like ? barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like ? barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: September 28, 2010
    Assignee: Purdue Research Foundation
    Inventors: Ray A. Bressan, Meena L. Narasimhan
  • Patent number: 7803556
    Abstract: The Proteins of the PR-5 family having a lectin-like ? barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like ? barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like ? barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like ? barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: September 28, 2010
    Assignee: Purdue Research Foundation
    Inventors: Ray A. Bressan, Meena L. Narasimhan
  • Publication number: 20090018065
    Abstract: The Proteins of the PR-5 family having a lectin-like P barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like P barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like ? barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like ? barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals.
    Type: Application
    Filed: December 26, 2007
    Publication date: January 15, 2009
    Inventors: Ray A. Bressan, Meena L. Narasimhan
  • Publication number: 20080177028
    Abstract: The Proteins of the PR-5 family having a lectin-like ? barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like ? barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like ? barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like ? barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals.
    Type: Application
    Filed: December 26, 2007
    Publication date: July 24, 2008
    Inventors: Ray A. Bressan, Meena L. Narasimhan